Particulate bioaerogels for respiratory drug delivery
Journal of Controlled Release · 2024-06 · 370 · 195-209
DOI: 10.1016/j.jconrel.2024.04.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-06. Verfasst von Hao-Ying Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom. Electronic address: hao-ying.li@kcl.ac.uk. Hauptthemen laut MEDLINE: Drug Delivery Systems, Gels. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome Leap.
Abstract (Originalsprache)
The bioaerogel microparticles have been recently developed for respiratory drug delivery and attract fast increasing interests. These highly porous microparticles have ultralow density and hence possess much reduced aerodynamic diameter, which favour them with greatly enhanced dispersibility and improved aerosolisation behaviour. The adjustable particle geometric dimensions by varying preparation methods and controlling operation parameters make it possible to fabricate bioaerogel microparticles with accurate sizes for efficient delivery to the targeted regions of respiratory tract (i.e. intranasal and pulmonary). Additionally, the technical process can provide bioaerogel microparticles with the opportunities of accommodating polar, weak polar and non-polar drugs at sufficient amount to satisfy clinical needs, and the adsorbed drugs are primarily in the amorphous form that potentially can facilitate drug dissolution and improve bioavailability. Finally, the nature of biopolymers can further offer additional advantageous characteristics of improved mucoadhesion, sustained drug release and subsequently elongated time for continuous treatment on-site. These fascinating features strongly support bioaerogel microparticles to become a novel platform for effective delivery of a wide range of drugs to the targeted respiratory regions, with increased drug residence time on-site, sustained drug release, constant treatment for local and systemic diseases and anticipated better-quality of therapeutic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom. Electronic address: hao-ying.li@kcl.ac.uk.
- Department of Engineering, Faculty of Natural & Mathematical Sciences, King's College London, WC2R 2LS, United Kingdom.
- Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom. Electronic address: ben.forbes@kcl.ac.uk.
Förderung
- Wellcome Trust
- Wellcome Leap
Zitieren
APA
Li, H. Y., Makatsoris, C., & Forbes, B. (2024). Particulate bioaerogels for respiratory drug delivery. Journal of Controlled Release, 370, 195-209. https://doi.org/10.1016/j.jconrel.2024.04.021
Vancouver
Li HY, Makatsoris C, Forbes B. Particulate bioaerogels for respiratory drug delivery. Journal of Controlled Release. 2024;370:195-209. doi:10.1016/j.jconrel.2024.04.021
BibTeX
@article{Li2024,
author = {Li, Hao-Ying and Makatsoris, Charalampos and Forbes, Ben},
title = {Particulate bioaerogels for respiratory drug delivery},
journal = {Journal of Controlled Release},
year = {2024},
volume = {370},
pages = {195--209},
doi = {10.1016/j.jconrel.2024.04.021}
}
EUVIMED